Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, ...

Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...

Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...

EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Amgen (AMGN) gains traction with a 26% YTD rise, strong earnings, and a robust dividend. Analysts signal growth potential ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...